Originally published In Press as doi:10.1074/jbc.M206046200 on September 15, 2002
J. Biol. Chem., Vol. 277, Issue 47, 45299-45305, November 22, 2002
Neuronal Differentiation-dependent Expression of the
Disialic Acid Epitope on CD166 and Its Involvement in Neurite Formation
in Neuro2A Cells*
Chihiro
Sato
§,
Tsukasa
Matsuda
, and
Ken
Kitajima
§¶
From the
Department of Applied Molecular Biosciences,
Graduate School of Bioagricultural Sciences, Nagoya University and the
§ Department of Animal Sciences, Division of Organogenesis,
Nagoya University Bioscience Center, Nagoya 464-8601, Japan
Received for publication, June 18, 2002, and in revised form, August 28, 2002
 |
ABSTRACT |
We previously demonstrated that
2,8-linked
disialic acid (diSia) residues occur in several glycoproteins of
mammalian brains (Sato, C., Fukuoka, H., Ohta, K., Matsuda, T.,
Koshino, R., Kobayashi, K., Troy, F. A., II, and Kitajima, K. (2000) J. Biol. Chem. 275, 15422-15431). The role of
the diSia epitope on these glycoproteins is not known, whereas the
importance of the diSia epitope on glycolipids is well documented in
neurite formation. In this study, we demonstrated that the diSia
epitope (Neu5Ac
2
8Neu5Ac
2
3Gal) on glycoproteins, but
not on glycolipids, is involved in neurite formation in a mouse
neuroblastoma cell line, Neuro2A, based on the following lines of
evidence. First, the amount of diSia epitope on glycoproteins increased
during retinoic acid-induced neurite formation. Second, retinoic acid
treatment primarily increased the diSia epitope on a 100-kDa
glycoprotein. We identified this protein as CD166 (SC1), an
immunoglobulin superfamily cell adhesion molecule involved in neurite
extension. Third, a monoclonal antibody against the diSia epitope
specifically inhibited neurite formation. We also demonstrated that
2,8-sialyltransferase III mRNA expression increased 1.7-fold after the induction of neurite formation, suggesting that
2,8-sialyltransferase III is responsible for formation of the diSia
epitope on CD166.
 |
INTRODUCTION |
Gangliosides are sialic acid-containing glycolipids that are
abundant in brains (1, 2).
2,8-Linked disialic acid
(diSia)1-containing and
trisialic acid-containing gangliosides (b and c series) in neuronal
cells are considered to have an important role in neurite formation.
Exogenous GD3 and GQ1c induce neurite sprouting and extension in a
murine neuroblastoma cell line, Neuro2A, and several other types of
neuronal cells (3, 4). Transfection of Neuro2A cells with the GD3
synthase cDNA leads to expression of GD3 and other b series
gangliosides and subsequent neurite formation (5, 6). In contrast,
however, parental Neuro2A cells form neurites without expressing b
or c series gangliosides endogenously when neurite formation is induced
by retinoic acid (5, 6). These observations led us to hypothesize that
the diSia residue might be linked to glycoproteins and that such an epitope might be involved in neurite differentiation of Neuro2A cells.
Until recently, there has been little attention paid to the presence of
di/oligoSia residues on glycoproteins, whereas the polysialic acid
(polySia) chain (degree of polymerization
8) has been
well studied in the neural cell adhesion molecule (NCAM) (7, 8) as well
as in fish polysialoglycoprotein (9). PolySia in NCAM is involved in
neural cell migration, axonal growth and path finding, synaptogenesis,
and synaptic functions associated with learning and memory (8). Using
recently developed highly sensitive techniques (10-12), we
demonstrated that glycoproteins containing di/oligoSia groups with up
to seven sialic residues occur in brain (10), and some other tissues
(13-15) occur more frequently than previously recognized. It is thus
hypothesized that these di/oligoSia moieties on glycoproteins have
important functions similar to those proposed for gangliosides (10,
16).
Therefore, we searched for the diSia-containing glycoproteins in
Neuro2A cells. In this study, we demonstrated the presence of the diSia
epitope on glycoproteins, most prominently on O-linked glycan(s) of the 100-kDa glycoprotein (100-kDa-gp) during neurite formation, while this epitope was deficient in glycolipids. We further
identified the 100-kDa-gp as CD166 (SC1), a member of the
immunoglobulin supergene family that is involved in heterophilic and
homophilic interactions during neuritogenesis (17). The antibody
against the diSia epitope inhibited neurite extension, indicating
the importance of the diSia epitope of this glycoprotein in retinoic
acid-induced neuronal differentiation. Considering these results
together with the critical roles of diSia-containing gangliosides
following exogenous addition to or expression in Neuro2A cells (3-6),
the diSia epitope either of the glycoprotein or the glycolipids might
have an important role in some steps of neurite formation. Thus, the
diSia epitope on glycoproteins might share a common function with that
of glycolipids. We further demonstrated that the
2,8-sialyltransferase (ST8Sia) III is expressed in the Neuro2A cells
and that its mRNA expression increases during neurite formation.
Therefore, ST8Sia III is suggested to be the enzyme responsible for the
biosynthesis of the diSia epitope on O-linked glycoproteins.
This finding is important because it shows a physiologic importance of
ST8Sia III in the neuronal system.
 |
EXPERIMENTAL PROCEDURES |
Materials--
NANase II (
2,3- and
2,6-specific
sialidase) was purchased from Toyobo (Tokyo, Japan). Clostridium
perfringens sialidase, acetylthiocholine,
5,5'-dithiobis-(2-nitrobenzoic acid), and BW284C51 were purchased from
Sigma. Arthrobacter ureafaciens sialidase was purchased from
Nacalai Co. (Kyoto, Japan). BCA protein assay kit was purchased
from Pierce. 1,2-Diamino-3,4-methylenedioxybenzene was purchased
from Dojindo (Kumamoto, Japan). Peptide:N-glycanase was
purchased from Takara (Kyoto Japan). ECL reagents were purchased from
Amersham Biosciences. Polyvinylidene difluoride (PVDF) membrane (Immobilon P) was a product of Millipore (Bedford, MA). Prestained molecular marker was purchased from Bio-Rad. Peroxidase-conjugated goat
anti-mouse IgG+IgM was purchased from American Qulex (San Clemente,
CA). Monoclonal antibody S2-566 (IgM), which specifically recognizes
the Neu5Ac
2
8Neu5Ac
2
3Gal sequence, and 12E3 (IgM),
which recognizes (Neu5Ac)n (n
5), were
generous gifts from Dr. Koichi Furukawa (Nagoya University School of
Medicine) and Dr. Tatsunori Seki (Juntendo University School of
Medicine), respectively. The purification of these antibodies was
described (10, 18). Mouse monoclonal antibody 2A11 (IgM), which
specifically recognizes the Neu5Ac
2
8Neu5Ac
2
6Glc was
prepared as descried previously (19). Fluorescein
isothiocyanate-conjugated goat anti-mouse IgG+IgM was purchased from
Seikagaku Co. (Tokyo, Japan). Goat anti-CD166 antibody and
peroxidase-conjugated rabbit anti-goat antibody were purchased from
Santa Cruz Inc. (Santa Cruz, CA) and Cappel (West Chester, PA),
respectively. Peroxidase-conjugated anti-hamster IgG antibody was
purchased from EY Laboratories (San Mateo, CA).
Cell Culture and Induction of Neuronal
Differentiation--
Murine neuroblastoma Neuro2A cells were cultured
in Dulbecco's modified Eagle's medium (Sigma) supplemented with 0.5 mg/ml of streptomycin sulfate, 100 units/ml of penicillin G, and 10% fetal bovine serum in a 5% CO2 and 95% air humidified
atmosphere at 37 °C. The cells were seeded at 1.0 × 106 and incubated for 24 h in a 90-mm-diameter plastic
dish. Then induction of neuritogenesis was performed as described (4, 20). Briefly, the differentiation was initiated by administration of 20 µM of retinoic acid (Sigma) in Dulbecco's modified
Eagle's medium supplemented with 2% fetal bovine serum. The culture
medium was routinely changed every 2 days. The morphology of the cells was observed under the microscope, and photographs were taken at ×100
magnification. To evaluate neuritogenesis quantitatively, the
differentiated cells were counted in five randomly chosen fields of
each dish. Cells bearing neurites with at least 1.5-fold longer than
the soma diameter were regarded as differentiated as described (21).
The activity of acetylcholinesterase was also measured as described
(22). Briefly, to the 40 µl of cell homogenates (see "SDS-PAGE and
Immunostaining") were added 50 µl of 2 mM
5,5'-dithiobis-(2-nitrobenzoic acid) in 0.1 M Tris-HCl (pH
8.0) and 10 µl of 5 mM acetylthiocholine in 0.1 M Tris-HCl (pH 8.0) and incubated at 25 °C for 30 min.
The enzyme reaction was stopped by the addition of 10 µl of
10
4 M BW284C51, and absorbance at 405 nm was measured.
Chemical Analysis--
Sialic acids were quantitated by the
fluorometric analysis using the
-keto acid-specific reagent
1,2-diamino-3,4-methylenedioxybenzene (23, 24). The internal sialic
acids were quantitated by the fluorometric
C7/C9 analysis as described previously (11).
The concentration of proteins was determined by the BCA protein assay kit or by the measurement of absorbance at 280 nm.
Preparation of the Glycoprotein and Glycolipid
Fractions--
For preparation of the glycoprotein and lipid
fractions, delipidation of the cells was carried out as described
previously (25, 26). The resulting precipitate and the organic phases were used as the glycoprotein and glycolipid fractions, respectively. The lipid fraction was dried and applied to a DEAE-Sephadex A-25 column
(CH3COO
form, chloroform/methanol/water = 30:60:8; 1 ml). The acidic lipid fraction was eluted with 5 vol of
methanol containing 0.3 M CH3COONH4
and analyzed by the fluorometric C7/C9 analysis
and TLC immunostaining (19) with the anti-diSia antibody S2-566 after
being desalted with Sephadex G-50 chromatography (0.8 × 20 cm, water).
SDS-PAGE and Immunostaining--
The cells were harvested
0-4 days after neuronal differentiation, washed with 10 mM
sodium phosphate (pH 7.2), 0.15 M NaCl (PBS), and
homogenized in PBS containing 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml of aprotinin, and leupeptin as described (10). The samples were dissolved in Laemmli buffer with or
without 5% mercaptoethanol and placed at 60 °C for 20 min. The
samples were then electrophoresed on 10% polyacrylamide gels and
electroblotted on the PVDF membrane using a semidry blotting apparatus.
The PVDF membrane was blocked with PBS containing 0.05% Tween 20 at
37 °C for 1 h. After being treated with or without NANase II (
2,3- and
2,6-specific sialidase) and
A. ureafaciens sialidase (
2,3-,
2,6-, and
2,8-specific sialidase) (500 milliunits/ml) at 37 °C for 20 h in 50 mM sodium acetate buffer (pH 5.5) or with peptide:N-glycanse treatment (25 milliunits/ml) at 37 °C
for 20 h in 0.125 M phosphate buffer (pH 8.2), the
membranes were incubated with the primary antibody, S2-566 (0.51 µg/ml), or 12E3 (6.0 µg/ml) at 4 °C for 16 h. As the
secondary antibody, the peroxidase-conjugated anti-mouse IgG+IgM (0.4 µg/ml) was used, and the color development was carried out as
described (10).
Immunofluorescence Microscopy--
Neuro2A cells were grown on
coverslips. For immunofluorescence, the culture medium was removed, and
the cells were fixed with 3% paraformaldehyde at 25 °C for 8 min,
followed by washing with PBS. The cells were then blocked with 2%
bovine serum albumin in PBS and incubated with the primary antibodies
(10 µg/ml for S2-566 and 30 µg/ml for 12E3) at 4 °C for 20 h. After washing with PBS, the cells were incubated with fluorescein
isothiocyanate-conjugated anti-mouse IgG+IgM (7 µg/ml) at 37 °C
for 30 min. After washing with PBS, the cells were observed under a
fluorescent microscope (Olympus).
Production of the Glutathione S-Transferase-CD166 Fusion
Protein--
A DNA fragment coding for a truncated form of the mouse
CD166 (U95030), lacking the N-terminal 27 amino acids and C-terminal 56 amino acids of the open reading frame, was amplified by PCR using the
following primers containing EcoRI or XhoI site:
5'-GTGAATTCTGGTACACTGTCAACTCAGC-3' and
5'-ATCTCGAGTTTTGCCTGGTCATTCACCT-3'. The amplified fragment (1499 bp) was subcloned into pGEX 4T-1 (Amersham Biosciences) through
the EcoRI and XhoI sites (pGEX-1). This plasmid
encodes the recombinant mouse CD166 consisting of glutathione
S-transferase followed by the truncated form of the mouse
CD166. The recombinant mouse CD166 was expressed and prepared as
described (14).
Preparation of Antisera against the Recombinant Mouse
CD166--
The recombinant mouse CD166 (20 µg/hamster) together with
Freund's complete adjuvant was intraperitoneally injected into the Syrian hamster (female, 6 weeks old). The animals were boosted twice
with the protein (20 µg/hamster) mixed with Freund's incomplete adjuvant every 2 weeks. Blood was collected 1 week after the last boost, and the serum was prepared as described (10).
Immunoprecipitation--
Balb/c mouse brain homogenate was
prepared as previously (10) and was subjected to immunoprecipitation
using the hamster anti-recombinant mouse CD166 (see above) and S2-566
antibodies after incubation with protein G-Sepharose as described
previously (14). In case of S2-566, protein G was preincubated with
rabbit anti-mouse IgM antibodies (Seikagaku Co.).
Antibody Treatment--
The cells were seeded at 1.0 × 104/well in a 24-well plate and incubated for 24 h.
The culture medium was changed to Dulbecco's modified Eagle's medium
containing 2% fetal bovine serum and 20 µM of retinoic
acid and with or without 0.1 µg/ml of monoclonal antibody S2-566 or
2A11 (day 0). The cells were incubated for 1-4 days. The culture
medium was routinely changed every 2 days. The morphology of the cells
was observed under the microscope, and photographs were taken at ×100
magnification. The length of neurite was measured as described above
(see "Cell Culture and Induction of Neuronal Differentiation").
Reverse Transcription-PCR--
The following degenerate
oligonucleotide primers for mouse proteins were used: ST8Sia I
(accession number X84235, nucleotides 48-1014),
5'-CATGCTAGCTCGGAAATTCC-3' and 5'-CGCGCCGATTTTGTGAAGAT-3'; ST8Sia II (X83562, nucleotides 46-1107),
5'-CTCGTGGTCTTCCTCATCTT-3' and 5'-GCCGACAGTCAGTTTCAATG-3'; ST8Sia III
(X80502, nucleotides 7-1101), 5'-AATTGCAAAATGGCCCGAGT-3' and
5'-ATGCATTCGATAGAGCAGCT-3'; ST8Sia IV (X86000, nucleotides 72-1061),
5'-AATAGCCAGAACTGAGGAGC-3' and 5'-CCTGTGGTCAGTTTTAGAGC-3'; ST8Sia V
(X98014, nucleotides 358-1140), 5'-AGGTGGAAGAGCCTCCAGAT-3' and
5'-CTTGGGCTTGACGTTGTCAT-3'; and GAPDH (M32599, nucleotides
5-1013), 5'-ACAAAATGGTGAAGGTCGGT-3' and
5'-TCCAGGGTTTCTTACTCCTT-3'. Total RNA was prepared from Neuro2A cells at days 0, 1, 2, 3, and 4 and mouse brain (Balb/c, 8 week female,
SLC Co. Japan) using Trizol (Invitrogen) according to the
manufacturer's instructions. Random-primed cDNA (~50 ng) from poly(A)+ RNA prepared by the oligo(dT) column
chromatography of total RNA was used as a template for PCR. Both sense
and antisense primers (25 pmol each) were added to a 50-µl reaction
mixture containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl2, 0.01% bovine serum albumin, all for dNTPs (each 200 µM), 1 unit of
Taq polymerase (Takara), and the template cDNA. 20-40
cycles were carried out on a thermal cycler; each cycle involved
incubation at 94 °C for 30 s, at 51 °C for 1 min, and at
72 °C for 2 min. The PCR amplification was found to be proportional
to the initial amount of the cDNAs with GAPDH and the number of
cycles (20-25 cycles) of PCR (data not shown). Aliquots of the PCR
products were separated on a 1.0% agarose gel and blotted onto
Hybond-N+ membranes (Amersham Biosciences). The membranes
were then probed with the indicated digoxigenin-labeled cRNAs (ST8Sia
I, II, III, IV, and V and GAPDH; nucleotides, 48-1014, 46-1107,
7-1101, 72-1061, 176-1140, and
5 to 1013, respectively) that had
been cloned from the mouse adult brain mRNAs for ST8Sia I-V and
GAPDH and sequenced (14).
 |
RESULTS |
Chemical Detection of the
2
8-linked Neu5Ac Residues on
Glycoproteins of Neuro2A Cells during Neurite Formation--
Neuro2A
cells can be differentiated into neuron-like cells with neurites after
addition of 20 µM of retinoic acid (4, 20). Morphologic changes such as neurite sprouting and extension started 1 day after treatment with retinoic acid (Fig.
1a). The proportion of
differentiated cells to the total cell number also increased (Fig.
1b), and at day 4, 90% of the cells had neurites. The
length of the neurite also increased as the retinoic acid incubation period increased (Fig. 1c). Acetylcholinesterase activity,
which is a marker enzyme for the cholinergic neuron-like
differentiation of Neuro2A (5, 21), also increased (Fig.
1d).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 1.
Neuronal cell differentiation of the murine
neuroblastoma cell line Neuro2A with retinoic acid. a,
morphologic changes of Neuro2A cells on the culture in the presence of
20 µM of retinoic acid. The photographs were taken at the
indicated day after the culture. Bar, 100 µm.
b, the proportion of the number of differentiated cells with
neurites to the total cell number at the indicated day. c,
the lengths of neurites as measured on the photograph as described
under "Experimental Procedures." d, the
acetylcholinesterase activity of the cell lysate (absorbance at 405 nm).
|
|
The Neuro2A cells were harvested every day after retinoic acid
treatment (days 0-4), and the glycoprotein fraction (completely delipidated cell lysate) was analyzed for the amount of internal Neu5Ac
(C9(Neu5Ac)) and terminal Neu5Ac (C7(Neu5Ac))
residues using fluorometric C7/C9 analysis. The
amount of internal Neu5Ac in the glycoprotein fraction increased (Fig.
2) with the increase in
acetylcholinesterase activity (Fig. 1d) and with the
morphologic changes (Fig. 1, a-c). The amount of terminal
Neu5Ac residues also increased, although it reached a plateau by day 2. These results suggest that the extensive formation of
2,8-linked
di/oligoNeu5Ac occurs at day 2 and later. The acidic glycolipid
fractions at days 0-4 were also analyzed by fluorometric
C7/C9 analysis, and no internal Neu5Ac was
detected (Table I). These chemical
results indicate that the
2,8-linked Neu5Ac structure on the
glycoprotein(s) of Neuro2A increases in a
differentiation-dependent manner.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 2.
Fluorometric C7/C9
analysis of the Neuro2A cells during retinoic acid-induced
differentiation. Neuro2A cells were cultured in the medium
containing 20 µM of retinoic acid and harvested on the
indicated day after incubation. The cell lysates were delipidated, and
the resultant glycoprotein samples were analyzed for the internal and
terminal Neu5Ac residues by the fluorometric
C7/C9 analysis. The detection of
C9(Neu5Ac) and C7(Neu5Ac) indicates the
presence of the internal Neu5Ac and the terminal Neu5Ac, respectively.
, internal Neu5Ac; , terminal Neu5Ac (1/100 scale).
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Composition of the internal and terminal Neu5Ac residues in the
glycoprotein and glycolipid fractions from Neuro2A cells before and
during the retinoic acid-induced differentiation
The values are the nmol of each Neu5Ac residue pmg of protein as
determined by the fluorometric C7/C9 analysis. ND, not
detected.
|
|
Immunochemical Detection of the diSia Epitope,
Neu5Ac
2
8Neu5Ac
2
3Gal, on Neuro2A Cells during
Neurite Formation--
To identify the diSia epitope-containing
molecule(s), Neuro2A cells of days 0-4 were subjected to
SDS-PAGE/Western blotting with the anti-diSia antibody S2-566, which
recognizes Neu5Ac
2
8Neu5Ac
2
3Gal (10), and the
anti-oligo/polySia antibody 12E3, which recognizes (Neu5Ac)n
(n
5) (18). The diSia epitope was prominently detected at 100 kDa, and the amount of the diSia epitope on the 100-kDa
glycoprotein (100-kDa-gp) increased as the neuronal differentiation proceeded (Fig. 3a). In
contrast, there was no immunostained band with 12E3 (Fig.
3b). Thus, the oligo/polySia (degree of polymerization
5) does not occur in glycoproteins in Neuro2A cells. The acidic lipid fraction of Neuro2A cells was not immunostained with S2-566 on
the high performance thin layer chromatography/immunostaining, indicating the absence of diSia-containing gangliosides like GD3 (data not shown). This is consistent with previous reports that Neuro2A
cells contain negligible amounts of GD3 and other b series gangliosides
(5, 6, 21, 27). The immunoblotting results were consistent with the
immunofluorescence of Neuro2A cells (Fig. 4). Immunofluorescence of the Neuro2A
cells before (day 0) and after neuronal differentiation (day 4) was
examined using S2-566 and 12E3. The cell surface was clearly
immunostained with S2-566 at day 4 when the cells were fully
differentiated (Fig. 4). On the other hand, there was no staining with
12E3. The fluorescence of S2-566 at day 4 was much more intense than
that at day 0. These results indicate that the expression of the diSia
epitope on the cell surface increased during the retinoic acid-induced
differentiation of the Neuro2A cells. This is consistent with the
results of the fluorometric C7/C9 analysis
(Table I) and the immunostaining of S2-566 (Fig. 3a).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 3.
SDS-PAGE/Western blotting of the Neuro2A cell
homogenates during differentiation. Neuro2A cells were cultured in
the medium containing 20 µM of retinoic acid and
harvested on the indicated day after the incubation. The cell
homogenate was separated by SDS-PAGE and electroblotted on the PVDF
membrane. The membrane was then subjected to the immunostaining with
the anti-diSia antibody S2-566 (0.51 µg/ml) (a) and the
anti-oligo/polySia antibody 12E3 (6.0 µg/ml) (b). The
homogenates of the Neuro2A cells on days 0-4 and the mouse adult brain
(5 µg protein/lane) were analyzed. The molecular masses of the
standard proteins are shown on the left of the
panels. To right of each panel, the
closed arrowhead represents the 100-kDa-gp, and the
open arrowheads represent 58-, 53-, 48-, 44-, and 38-kDa
glycoproteins.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
Immunofluorescence of the differentiated
Neuro2A cells using the anti-diSia and anti-oligo/polySia
antibodies. The cells before (day 0) and 4 days after (day 4) the
retinoic acid treatment were fixed with 3% paraformaldehyde and
immunostained with the anti-diSia (S2-566) (10 µg/ml) and
anti-oligo/polySia (12E3) (30 µg/ml) antibodies as described under
"Experimental Procedures." The photos of immunofluorescence of
Neuro2A cells are shown. Bar, 10 µm.
|
|
Characterization of the diSia Epitope of the 100-kDa Glycoprotein
in Neuro2A Cells and Mouse Adult Brains--
To further characterize
the diSia epitope of the 100-kDa-gp, we examined the sensitivity of the
stain to the linkage-specific sialidase treatments (Fig.
5, lanes 1-3). With A. ureafaciens sialidase, which cleaves
2
3,
2
6,
and
2
8 Neu5Ac linkages, the S2-566 stain of the 100-kDa-gp
band disappeared (Fig. 5, lane 3). On the other hand, with
NANase II, which cleaves
2
3 and
2
6 linkages,
the S2-566 stain remained (Fig. 5, lane 2). These results
confirmed that the diSia structure of the 100-kDa-gp contains the
Neu5Ac
2
8Neu5Ac linkage. Furthermore, S2-566 staining of the
100-kDa-gp was resistant to the peptide:N-glycanase
treatment (Fig. 5, lane 4), suggesting that the diSia
epitope is on O-glycan chain(s). The migration of the S2-566
stain of the 100-kDa-gp did not change under nonreducing conditions
(Fig. 5, lane 5), indicating that the 100-kDa-gp has no
intermolecular disulfide bonds. These results indicated that the
100-kDa-gp contains the Neu5Ac
2
8Neu5Ac
2
3Gal
epitope on the O-linked glycan chain(s). The 100-kDa-gp was
also detected in mouse brain homogenates by S2-566, together with five
other components at 58, 53, 48, 44, and 38 kDa (Fig. 3a).
The 100- and 58-kDa glycoproteins were prominently stained in mouse
adult brain. These observations were previously described (10). In
contrast, the 12E3 epitope was not observed except for a greater than
180-kDa NCAM as reported previously (28, 29). The S2-566 stain of the
100-kDa-gp derived from mouse adult brain had the same properties
(shown in Fig. 5) as that derived from the Neuro2A cells (data not
shown). These results together suggest that the 100-kDa-gp of mouse
adult brain is the same glycoprotein as that of Neuro2A cells.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 5.
Immunostaining of the Neuro2A cell
homogenates with the anti-diSia antibody S2-566. The Neuro2A cell
homogenate of day 2 was subjected to SDS-PAGE under reducing conditions
and blotted to the PVDF membranes. The membrane was untreated
(lane 1) or treated with NANase II ( 2,3- and
2,6-specific sialidase, 0.50 unit/ml) (lane 2), A. ureafaciens sialidase ( 2,3-, 2,6-, and 2,8-specific
sialidase, 0.50 unit/ml) (lane 3), or
peptide:N-glycanase (lane 4) (25 milliunits/ml)
for 20 h prior to the immunostaining with S2-566 (0.51 µg/ml) as
described under "Experimental Procedures." The homogenates of
Neuro2A cells from day 2 were separated on the SDS-PAGE under the
nonreducing conditions and blotted on the PVDF membrane. The membrane
was subjected to the immunostaining with S2-566 (lane
5).
|
|
Identification of the 100-kDa Glycoprotein as CD166--
The
results described above as well as our previous results (10) clearly
indicate that the 100-kDa-gp is the diSia-containing glycoprotein in
mouse adult brain. Notably, it was previously suggested that rat
lymphocytes also express the diNeu5Gc-containing glycoprotein at 100 kDa (30). We thus hypothesized that the 100-kDa-gp was a common
diSia-containing glycoprotein between brain and lymphocytes. One such
candidate glycoprotein was CD166 (SC1), because CD166 is a common
glycoprotein between brain and thymus, and the molecular mass is
95-100 kDa under either reducing or nonreducing conditions (17). To
determine whether the 100-kDa-gp is CD166, we developed antisera by
immunizing hamsters with recombinant mouse CD166. The recombinant
glutathione S-transferase-CD166 protein was immunostained
with commercially available goat anti-CD166 antibodies that
specifically recognize the CD166 but could not immunoprecipitate the
CD166 glycoprotein (data not shown). The obtained hamster anti-mouse
CD166 antibodies immunoprecipitated mouse CD166. Immunoprecipitated
CD166 was immunostained with S2-566, and inversely immunoprecipitated
S2-566 epitope-containing 100-kDa-gp was immunostained with the hamster
anti-mouse CD166 antibodies (Fig. 6). The
100-kDa-gp of differentiated Neuro2A cells was also identified as CD166
in the same way (data not shown). These results clearly indicate that
the Neu5Ac
2
8Neu5Ac
2
3Gal epitope-containing 100-kDa-gp is CD166.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 6.
Immunodetection of the diSia epitope in CD166
immunopurified from mouse brain. The mouse CD166
immunoprecipitated from mouse brain homogenates using hamster
anti-recombinant mouse CD166 antibodies (IP:CD166) was
immunostained with anti-mouse CD166 antibodies (IB:CD166)
and S2-566 (IB:S2-566). The diSia-containing
100-kDa-gp immunoprecipitated from mouse brain homogenates using
mouse S2-566 antibodies (IP:S2-566) was immunostained with
anti-mouse CD166 antibodies (IB:CD166) and S2-566
(IB:S2-566). IP, immunoprecipitation;
IB, immunoblot.
|
|
Effect of the Anti-diSia Antibodies on Neurite Outgrowth in
Neuro2A--
To evaluate the importance of the diSia epitope in
neuronal differentiation, the cells were incubated with or without the anti-diSia monoclonal antibodies S2-566 and 2A11. The 2A11 recognizes Neu5Ac
2
8Neu5Ac
2
6Glc (Glc is required). The neurite
lengths at days 0-4 were measured. There were obvious differences in
neurite length between the cells incubated with S2-566 and those with 2A11 at days 3 and 4, although there were very few differences on days
1 and 2 (Fig. 7). Neurite extension was
inhibited with 0.1 µg/ml of S2-566, whereas no inhibition was
observed with 2A11, even at concentrations of up to 5 µg/ml. In the
same way, there was no inhibition with the anti-oligo/polySia antibody
12E3 (data not shown). The inhibitory effects of the antibodies on
neurite extension appear to be correlated with the reactivity of these antibodies to the 100-kDa-gp (Figs. 3 and 4). The increase of the
2,8-linked Neu5Ac compared with terminal Neu5Ac (Fig. 2), which
indicates extensive formation of the diNeu5Ac epitope, is coincidental
with the inhibitory effects of the neurite outgrowth by S2-566 (Fig.
7). These results indicate that the Neu5Ac
2
8Neu5Ac
glycosidically linked to the 3-position of the Gal residue is important
for the neurite outgrowth, especially at later stages.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of the monoclonal antibodies S2-566
and 2A11 on neurite outgrowth in Neuro2A. Neuro2A cells were
cultured in the medium containing 20 µM of retinoic acid
in the absence ( ) or presence ( ) of the monoclonal antibodies
S2-566 and 2A11 ( ) (0.1 µg/ml). At days 0-4, the length of
neurite was measured as described under "Experimental
Procedures."
|
|
Expression of the
2
8-Sialyltransferase mRNAs during
Neurite Formation of Neuro2A Cells--
To understand the biosynthesis
of the diSia structure of the glycoprotein, we analyzed the Neuro2A
cells during differentiation for the expression of mRNAs for the
five known
2,8-sialyltransferases using reverse
transcription-polymerase chain reaction. ST8Sia I (31) and ST8Sia V
(32) use glycolipids as substrates and ST8Sia II (or STX) (33,
34) and ST8Sia IV (or PST) (35) use glycoproteins, especially NCAM.
ST8Sia III synthesizes the diSia structure both on glycoproteins and
glycolipids in vitro (36). Only ST8Sia III was expressed in
Neuro2A cells at every stage of neuronal differentiation (Fig.
8a). No other ST8Sia mRNAs were detected, even using highly sensitive digoxigenin-labeled probes (data not shown). Consistent with this observation, it was
previously reported that Neuro2A cells express only ST8Sia III before
neuronal differentiation, although there is no description for the
expression after differentiation (37). These results are consistent
with the observation that Neuro2A cells do not express any b or c
series gangliosides but express the diSia structure on CD166.
Semi-quantitative analysis of the ST8Sia III mRNA was performed,
and its expression level increased 1.4-fold at day 1 and 1.7-fold at
day 4 after neuronal differentiation (Fig. 8b). These
results suggest that ST8Sia III is the enzyme responsible for the
formation of the diSia on CD166 and that the increase of the diSia
epitope on CD166 is due to the up-regulation of ST8Sia III
expression.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 8.
Reverse transcription-PCR for the mRNAs
for ST8Sia I-V and GAPDH in Neuro2A cells and mouse adult brain.
a, reverse transcription-PCR was carried out using cDNAs
prepared from the Neuro2A cells at 0-4 days post-differentiation as
templates and primers as described under "Experimental Procedures."
Aliquots of the PCR products amplified for 40 cycles were analyzed for
the expression of the mRNAs for ST8Sia I-V and GAPDH by the 1.0%
agarose gel electrophoresis. As positive controls, mouse adult brain
was used for the detection of these mRNAs. b,
semi-quantitative analysis of the amount of the mRNA for ST8Sia III
with GAPDH as internal control. The PCR products amplified at 20 cycles
using primers for ST8Sia III and GAPDH were analyzed by 1.0% agarose
gel electrophoresis. The values are amounts of the ST8Sia III cDNA
at each day relative to those at day 0 (set equal to 100%).
|
|
 |
DISCUSSION |
The relation between neuronal differentiation and the expression
of gangliosides is well studied in Neuro2A cells (3-6). Neuro2A cells
differentiate into cholinergic neuron-like cells following retinoic
acid treatment (3, 4). Neuritogenesis can be induced in the absence of
retinoic acid by exogenous addition of the diSia epitope
(Neu5Ac
2
8Neu5Ac
2
3Gal)-containing gangliosides (GD3
and the b series) (4) or by forced expression of GD3 and the b series
gangliosides on the cells by transfection with GD3 synthase cDNA
(5, 6). These results strongly suggest the importance of cell surface
expression of the diSia epitope in neuritogenesis. It was previously
demonstrated, however, that the parental Neuro2A cells do not express
GD3 or b series gangliosides (5, 6). In the present study, the
differentiated Neuro2A cells also did not express these gangliosides.
Therefore, we suspect that the diSia epitope is expressed on
glycoproteins, but not glycolipids, during neuritogenesis.
Chemical and immunochemical analyses unequivocally showed that the
diSia epitope, but not the oligo/polySia epitope
((
2
8Neu5Ac)n, n
5), was expressed
in several glycoproteins, primarily in the 100-kDa-gp in Neuro2A cells
(Figs. 3 and 4), whereas the diSia epitope was not expressed on
glycolipids. Using immunoprecipitation experiments, we identified the
100-kDa-gp to be the CD166 that is expressed in Neuro2A cells as well
as in mouse adult brains. The CD166 is a membrane-spanning glycoprotein belonging to the immunoglobulin superfamily that is also named SC1/BEN/DM-GRASP (38-40). The CD166 is a cell adhesion molecule that
has homophilic binding activity as well as heterophilic binding activity to CD6, 30-35-kDa protein, and NgCAM (17, 38, 41). In chicken
brain, CD166 might be involved in neurite extension of spinal motor
neurons (42). In mouse, CD166 is also involved in the path finding
and/or fasciculation of specific cranial sensory nerve fibers (43).
Anti-CD166 antibody inhibits neurite extension (39, 41). Thus, CD166 is
closely associated with neurite formation. Our finding that the diSia
epitope was present on CD166 raises the possibility that the diSia
epitope is involved in the CD166-associated path finding and
fasciculation. In fact, the following lines of evidence support the
possibility and suggest that the diSia epitope on CD166 is important
for neurite formation of Neuro2A cells. First, expression of the diSia
epitope on CD166 increases during retinoic acid-induced differentiation
(Fig. 4). Second, the increase of diSia on CD166 is concomitant with
the morphologic and biochemical changes in neuronal differentiation of
the Neuro2A cells (Figs. 1-4). Third, the anti-diSia antibody S2-566
(specific to Neu5Ac
2
8Neu5Ac
2
3Gal sequence; the Gal
residue is necessary) (10) inhibited neurite extension (Fig. 7),
whereas there was no inhibition by the 2A11 antibody (recognizing
Neu5Ac
2
8Neu5Ac
2
6Glc sequence; the Glc residue is
necessary) (19) or the anti-oligo/polySia antibody 12E3. Notably, the
inhibitory effect of the S2-566 appears to be associated with later
stages of neurite formation rather than the earlier stages (Fig. 7). It
remains to be determined how the antibody differentially inhibits later
stages of neurite extension. It is interesting to note, however, that
the later stages correspond to the state in which cells actively
express the diSia on glycoproteins (Fig. 2).
At present, it is not clear how the diSia epitope on CD166 is important
for neurite formation, but the diSia epitope on CD166 might influence
neurite formation in a different way than polySia on the NCAM does. The
polySia on NCAM is considered to be involved in the inhibition of
neurite outgrowth through its anti-adhesive effect on the NCAM-mediated
cell adhesion. On the other hand, the diSia epitope on CD166 might be
involved in neurite outgrowth possibly through the facilitating effect
of the diSia on CD166-mediated homophilic adhesion or heterophilic
interaction with associative counterpart molecules that specifically
recognize the diSia epitope, like siglecs (sialic acid-binding
immunoglobulin-like lectins) (44), as suggested by the fact that the
anti-diSia antibody specifically blocked neurite extension (Fig. 7).
Therefore, discovery of associative counterpart molecule(s), which
specifically recognize the Neu5Ac
2
8Neu5Ac
2
3Gal
sequence, might help to determine the underlying mechanism for this
phenomenon. In this regard, siglec 11 has most recently been cloned and
is expressed not only in macrophages of various tissues, like liver
Kupffer cells, but also in brain microglia. This siglec recognizes the
2,8-linked sialic acid specifically, although a murine orthologue
has not yet been found (45). We are now searching for the diSia-binding factor and the mechanism of neurite extension through the diSia epitope.
In Neuro2A cells, the diSia epitope is exclusively linked to
glycoproteins but not to glycolipids. In mouse brain, however, the
diSia epitope is present in both glycoproteins and glycolipids, which
are often colocalized on the same cells. Therefore, the diSia epitope
can be regarded as the common glycotope in brain. Whether the diSia
epitope on either or both glycoproteins and glycolipids is of
biological importance is an interesting question. A recent report that
mice deficient in GD3 synthase (ST8Sia I) genes can develop normally
(46) is suggestive in this regard. These mice cannot synthesize the
disialylated b series gangliosides. We do not know that they can
express the diSia epitope on glycoproteins like CD166, but it is
possible that these mice express the diSia epitope on glycoproteins,
because ST8Sia III is responsible for the synthesis of this epitope
(Fig. 8). The diSia epitope in glycoproteins might compensate for the
roles of the diSia-containing gangliosides. With respect to the common
glycotopes, (Neu5Gc)GD1c and the diNeu5Gc-containing 100-kDa
glycoprotein are colocalized in rat T cells. In the case of rat T
cells, the common glycotope is Neu5Gc
2
8Neu5Gc and the
diNeu5Gc epitope of either glycolipids or the glycoproteins might be
functional in the CD4-GD1c epitope-mediated T cell activation (30).
Notably, CD166 (also called an activated leukocyte cell adhesion
molecule) is also expressed on activated T cells and epithelia (17).
The diNeu5Gc-containing 100-kDa glycoprotein in thymus is also
CD166.2 The functional
importance of CD166 and the diSia epitope in thymus is not yet known.
Taken together, it appears that the common glycotope has common roles
in brain and thymus, and elucidation of the functions of the common
glycotopes in those tissues is underway in our laboratory.
ST8Sia III is the enzyme responsible for the synthesis of the diSia
epitope during differentiation in Neuro2A cells (Fig. 8). The absence
in the Neuro2A cells of ST8Sia I and ST8Sia V, which are both
responsible for the synthesis of the diSia epitope on glycolipids, is
consistent with the fact that Neuro2A cells have no GD3 or b or c
series gangliosides. Neuro2A cells do not express ST8Sia II (or
STX) or ST8Sia IV (or PST), which is responsible for the formation of
the polySia structure on glycoproteins, especially on NCAM. This is
consistent with the fact that there is a negligible amount of
polysialylated NCAM in the Neuro2A cells (Fig. 4). The expression of
ST8Sia III mRNA is 1.4-1.7-fold up-regulated after treatment of
the cells with retinoic acid. This up-regulation of ST8Sia III mRNA
expression is consistent with the increase in the amount of internal
Neu5Ac residues as well as in the intensity of S2-566 immunostaining on
CD166. In the 5'-flanking regions, ST8Sia III has an AP-2 site that is
able to respond to retinoic acid is implicated in the regulation of
neural development and myeloid cell differentiation (47, 48). The
expression of ST8Sia III does not lead to in vivo synthesis
of GD3 in the Neuro2A cells, although ST8SiaIII has the ability to
synthesize the diSia epitope on glycolipids in vitro (36).
The physiologic substrate of ST8Sia III has long remained unknown,
until our recent finding that adipoQ (ACRP30 or adiponectin), which is
a cytokine secreted from adipose tissue (49, 50), is a substrate of
ST8Sia III (14). ST8Sia III is expressed in adipose tissue and
up-regulated during adipocyte differentiation (14). AdipoQ, which is
secreted exclusively from 3T3-L1 cells, contains the diSia epitope on
its O-linked glycan chain (14). In CD166, the diSia epitope
appears to be attached to the O-linked glycan chain(s) (Fig.
5). Thus, ST8Sia III might be a disialic acid synthase that is involved
in the synthesis of diSia-containing O-linked glycoproteins
in various tissues.
 |
FOOTNOTES |
*
This work was supported in part by Grants-in-aid for
Scientific Research 13680686 (to K. K.) and 14780471 (to C. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of Animal
Sciences, Div. of Organogenesis, Nagoya University Bioscience Center,
Nagoya 464-8601, Japan. E-mail:
kitajima@agr.nagoya-u.ac.jp.
Published, JBC Papers in Press, September 15, 2002, DOI 10.1074/jbc.M206046200
2
C. Sato, T. Matsuda, and K. Kitajima,
manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
diSia, disialic
acid;
oligoSia, oligosialic acid;
polySia, polysialic acid;
PBS, phosphate-buffered saline;
PVDF, polyvinylidene difluoride;
ST8Sia,
-2,8-sialyltransferase;
NCAM, neural cell adhesion molecule;
100-kDa-gp, 100-kDa glycoprotein;
GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
 |
REFERENCES |
| 1.
|
Nagai, Y.,
and Iwamori, M.
(1996)
in
Biology of the Sialic Acids
(Rosenberg, A., ed)
, pp. 197-241, Plenum Press, New York
|
| 2.
|
Sharon, N.,
and Lis, H.
(1997)
in
Glycosciences
(Gabius, H.-J.
, and Gabius, S., eds)
, pp. 133-189, Chapman & Hall, Weinheim, Germany
|
| 3.
|
Leeden, R. W.
(1984)
J. Neurosci. Res.
12,
147-159[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Tsuji, S.,
Yamashita, T.,
Tanaka, M.,
and Nagai, Y.
(1988)
J. Neurochem.
50,
414-423[Medline]
[Order article via Infotrieve]
|
| 5.
|
Kojima, N.,
Kurosawa, N.,
Nishi, T.,
Hanai, N.,
and Tsuji, S.
(1994)
J. Biol. Chem.
269,
30451-30456[Abstract/Free Full Text]
|
| 6.
|
Liu, H.,
Kojima, N.,
Kurosawa, N.,
and Tsuji, S.
(1997)
Glycobiology
7,
1067-1076[Abstract/Free Full Text]
|
| 7.
|
Troy, F. A., II
(1996)
in
Biology of the Sialic Acids
(Rosenberg, A., ed)
, pp. 95-144, Plenum Press, New York
|
| 8.
|
Brués, J. L.,
and Rutishauser, U.
(2000)
in
Molecular and Cellular Glycobiology
(Fukuda, M.
, and Hinsgaul, O., eds)
, pp. 116-132, Oxford University Press, New York
|
| 9.
|
Inoue, Y.
(1992)
in
Polysialic Acids
(Roth, J.
, Rutishauser, U.
, and Troy, F. A., II, eds)
, pp. 171-182, Birkhäuser Verlag, Basel, Switzerland
|
| 10.
|
Sato, C.,
Fukuoka, H.,
Ohta, K.,
Matsuda, T.,
Koshino, R.,
Kobayashi, K.,
Troy, F. A., II,
and Kitajima, K.
(2000)
J. Biol. Chem.
275,
15422-15431[Abstract/Free Full Text]
|
| 11.
|
Sato, C.,
Inoue, S.,
Matsuda, T.,
and Kitajima, K.
(1998)
Anal. Biochem.
261,
191-197[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Sato, C.,
Inoue, S.,
Matsuda, T.,
and Kitajima, K.
(1999)
Anal. Biochem.
266,
102-109[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Sato, C.,
Kitajima, K.,
Inoue, S.,
and Inoue, Y.
(1998)
J. Biol. Chem.
273,
2575-2582[Abstract/Free Full Text]
|
| 14.
|
Sato, C.,
Yasukawa, Z.,
Honda, N.,
Matsuda, T.,
and Kitajima, K.
(2001)
J. Biol. Chem.
276,
28849-28856[Abstract/Free Full Text]
|
| 15.
|
Nadanaka, S.,
Sato, C.,
Kitajima, K.,
Katagiri, K.,
Irie, S.,
and Yamagata, T.
(2001)
J. Biol. Chem.
276,
33657-33664[Abstract/Free Full Text]
|
| 16.
|
Sato, C.,
and Kitajima, K.
(1999)
Trends Glycosci. Glycotechnol.
11,
371-390
|
| 17.
|
Bowen, M. A.
(2002)
in
Leukocyte Typing VII
(Mason, D., ed)
, pp. 894-895, Oxford University Press, Oxford
|
| 18.
|
Sato, C.,
Kitajima, K.,
Inoue, S.,
Seki, T.,
Troy, F. A., II,
and Inoue, Y.
(1995)
J. Biol. Chem.
270,
18923-18928[Abstract/Free Full Text]
|
| 19.
|
Ohta, K.,
Sato, C.,
Matsuda, T.,
Toriyama, M.,
Vacquier, V. D.,
Lennarz, W. J.,
and Kitajima, K.
(2000)
Glycoconj. J.
17,
205-214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Riboni, L.,
Prinetti, A.,
Bassi, R.,
Caminiti, A.,
and Tettamanti, G.
(1995)
J. Biol. Chem.
270,
26868-26875[Abstract/Free Full Text]
|
| 21.
|
Hasegawa, T.,
Yamaguchi, K.,
Wada, T.,
Takeda, A.,
Itoyama, Y.,
and Miyagi, T.
(2000)
J. Biol. Chem.
275,
8007-8015[Abstract/Free Full Text]
|
| 22.
|
Doctor, B. P,
Toker, L.,
Roth, E.,
and Silman, I.
(1987)
Anal. Biochem.
166,
399-403[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Nakamura, M.,
Hara, S.,
Yamaguchi, M.,
Takemori, Y.,
and Ohkura, Y.
(1987)
Chem. Parma. Bull.
35,
687-692
|
| 24.
|
Hara, S.,
Yamaguchi, M.,
Takemori, Y.,
and Nakamura, M.
(1986)
J. Chromatogr.
377,
111-119[Medline]
[Order article via Infotrieve]
|
| 25.
|
Folch-Pi, J.,
Arsove, S.,
and Meath, J. A.
(1951)
J. Biol. Chem.
191,
819-831[Free Full Text]
|
| 26.
|
Brown, D. A.,
and Rose, J. K.
(1992)
Cell
68,
533-544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Prinetti, A.,
Iwabuchi, K.,
and Hakomori, S.
(1999)
J. Biol. Chem.
274,
20916-20924[Abstract/Free Full Text]
|
| 28.
|
Seki, T.,
and Rutishauser, U. N.
(1998)
J. Neurosci.
18,
3757-3766[Abstract/Free Full Text]
|
| 29.
|
Eckhardt, M.,
Bukalo, O.,
Chazal, G.,
Wnag, L.,
Goridis, C.,
Schachner, M.,
Gerardy-Schahn, R.,
Cremer, H.,
and Dityatev, A.
(2000)
J. Neurosci.
20,
5234-5244[Abstract/Free Full Text]
|
| 30.
|
Nohara, K.,
Kunimoto, M.,
and Fujimaki, H.
(1998)
J. Biochem. (Tokyo)
124,
194-199[Abstract/Free Full Text]
|
| 31.
|
Haraguchi, M.,
Yamashiro, S.,
Yamamoto, A.,
Furukawa, K.,
Takamiya, K.,
Loys, K. O.,
Shuku, H.,
and Furukawa, K.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
10455-10459[Abstract/Free Full Text]
|
| 32.
|
Kohno, M.,
Yoshida, Y.,
Kurosawa, N.,
Kojima, N.,
and Tsuji, S.
(1996)
J. Biol. Chem.
271,
29366-29371[Abstract/Free Full Text]
|
| 33.
|
Livingston, B. D.,
and Paulson, J.
(1993)
J. Biol. Chem.
268,
11504-11507[Abstract/Free Full Text]
|
| 34.
|
Kojima, N.,
Yoshida, Y.,
and Tsuji, S.
(1995)
FEBS Lett.
6,
119-122
|
| 35.
|
Eckhart, M.,
Mühlenhoff, M.,
Bethe, A.,
Koopman, J.,
Frosch, M.,
and Gerardy-Schahn, R.
(1995)
Nature
373,
213-249
|
| 36.
|
Yoshida, Y.,
Kojima, N.,
Kurosawa, N.,
Hamamoto, T.,
and Tsuji, S.
(1995)
J. Biol. Chem.
270,
14628-14633[Abstract/Free Full Text]
|
| 37.
|
Takashima, S.,
Tachida, Y.,
Nakagawa, T.,
Hamamoto, T.,
and Tsuji, S.
(1999)
Biochem. Biophys. Res. Commun.
260,
23-27[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Tanaka, H.,
Matsui, T.,
Agata, A.,
Tomura, M.,
Kubota, I.,
McFarland, K. C.,
Kohr, B.,
Lee, A.,
Phillips, H. S.,
and Shelton, D. L.
(1991)
Neuron
7,
535-545[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Burrns, F. R.,
von Kannen, S.,
Guy, L.,
Raper, J. A.,
Kamholz, J.,
and Chang, S.
(1991)
Neuron
7,
209-220[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Pourquie, O.,
Hallonet, M. E. R.,
and Le Douarin, N. M.
(1992)
J. Neurosci.
12,
1548-1557[Abstract]
|
| 41.
|
DeBernardo, A. P.,
and Cheng, S.
(1996)
J. Cell Biol.
133,
657-666[Abstract/Free Full Text]
|
| 42.
|
DeBernardo, A. P.,
and Cheng, S.
(1995)
Dev. Biol.
169,
65-75[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Sekine-Aizawa, Y.,
Omori, A.,
and Fujita, S. C.
(1998)
Eur. J. Neurosci.
10,
2810-2824[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Crocker, P. R.,
and Varki, A.
(2001)
Trends Immunol.
22,
337-342[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Angata, T.,
Kerr, S. C.,
Greaves, D. R.,
Varki, N. M.,
Crocker, P. R.,
and Varki, A.
(2002)
J. Biol. Chem.
277,
24466-24474[Abstract/Free Full Text]
|
| 46.
|
Kawai, H.,
Allende, M. L.,
Wada, R.,
Kono, M.,
Sango, K.,
Deng, C.,
Miyakawa, T.,
Crawley, J. N.,
Werth, N.,
Bierfreund, U.,
Sandhoff, K.,
and Proia, R. L.
(2001)
J. Biol. Chem.
276,
6885-6888[Abstract/Free Full Text]
|
| 47.
|
Zhang, J.,
Hagopian-Donaldson, S.,
Serbedzija, G.,
Elsemore, J.,
Plehn- Dujowich, D.,
McMahon, A. P.,
Flavell, R. A.,
and Williams, T.
(1996)
Nature
381,
238-241[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Yoshida, Y.,
Kurosawa, K.,
Kanematsu, T.,
Taguchi, A.,
Arita, M.,
Kojima, N.,
and Tsuji, S.
(1996)
Glycobiology
6,
573-580[Abstract/Free Full Text]
|
| 49.
|
Hu, E.,
Liang, P.,
and Spiegelman, B. M.
(1996)
J. Biol. Chem.
271,
10697-10703[Abstract/Free Full Text]
|
| 50.
|
Yamaguchi, T.,
Kamon, J.,
Waki, H.,
Terauchi, Y.,
Kubota, N.,
Hara, K.,
Mori, Y.,
Ide, T.,
Murakami, T.,
Tsuboyama, K. N.,
Ezaki, O.,
Akanuma, Y.,
Gavrilova, O.,
Vinson, C.,
Reitman, M. L.,
Kagechika, H.,
Shudo, K.,
Yoda, M.,
Nakano, Y.,
Tobe, K.,
Nagai, R.,
Kimura, S.,
Tomita, M.,
Froguel, O.,
and Kadowaki, T.
(2001)
Nature
7,
941-946[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles: